Inviragen Presents to Global Public Health Community

FORT COLLINS, Colo.--(BUSINESS WIRE)--Dr. Dan T. Stinchcomb, Inviragen’s Chief Executive Officer, will present the company’s vaccine development plans today at the 2008 Partnering for Global Health Forum. The forum is organized by BIO Ventures for Global Health and the Biotechnology Industry Organization and the meeting is sponsored by the Bill & Melinda Gates Foundation.

“It is an honor for Inviragen to be selected to review its vaccine technologies and business plans at the Partnering for Global Health Forum,” said Dr. Stinchcomb. “Inviragen is presenting in sessions alongside larger biopharmaceutical and vaccine companies as well as major public health foundations and experts.” To develop its dengue vaccine, Inviragen has partnered with the Pediatric Dengue Vaccine Initiative, Shantha Biotechnics in India, the Division of Vector-Borne Infectious Diseases of the Centers for Disease Control and Prevention, the University of Wisconsin, and the National Institutes of Allergy and Infectious Diseases. Through these collaborations, Inviragen plans to bring a safe and effective dengue vaccine to markets across the globe.

About Inviragen

Co-founded by Dr. Jorge Osorio and Dr. Dan Stinchcomb, Inviragen is developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen is developing a vaccine to protect against dengue fever for global markets, a vaccine to protect against West Nile for the U.S. markets, a combination plague and smallpox vaccine for biodefense, and an avian influenza vaccine. InViragen has offices in Fort Collins, Colorado and Madison, Wisconsin. Please see www.inviragen.com for more details.